TNBC

Merck’s Keytruda fails in Phase III triple-negative breast cancer study, but has a few more chances

The KEYNOTE-119 study failed to show a survival benefit in TNBC patients. The news comes two months after the FDA gave accelerated approval to a rival, Roche's Tecentriq.

By Alaric DeArment

BioPharma

Roche’s Tecentriq approved as first immunotherapy drug for breast cancer

The drug received accelerated approval for combination with Celgene's Abraxane based on Phase III data. According to a study, PD-L1-positive patients account for 26 percent of TNBC patients overall.

By Alaric DeArment

Enhanced Direct Enrollment: Georgia Access and the Power of Partnership

Across the nation, state-based health insurance exchanges are searching for ways to better serve their communities while making enrollment easier, more personal, and more accessible for everyone.

By Heather Korbulic - GetInsured

Discover the Most Effective Aquatic Therapy Programs in Chicago Suburbs

Incorporating aquatic therapy can enhance patient outcomes and shorten recovery times for health care professionals. In the Chicago suburbs, the demand for such programs is rising.

By FYZICAL Therapy & Balance Centers

The Top EAP Companies for Mental Health Support

Employee assistance programs have become essential tools for organizations aiming to address mental health challenges, reduce burnout and foster healthier workplaces.

By AllOne Health